You are here



Feb 2017   Congress taking place 19-21 May 2017 in Teaneck NJ carries 16 CME credits on evidence-based research and products derived from Perinatal sources.
Feb 2017   Despite the hurdles, great therapeutic value can be gained from the MSCs in the Wharton’s Jelly of Cord Tissue, which are being employed in an ever-increasing portfolio of indications.
Feb 2017   Available exclusively from Cordlife, CellOptima™ is a proprietary technology which can isolate and expand two types of stem cells: MSC and EpSC, from the lining of the newborn's umbilical cord.


Jan 2017   There are more advanced cell therapy clinical trials with other sources of perinatal cells than there are with cord blood, either cumulatively or by year.
Jan 2017   When he was 12 days old Jack became the youngest person ever to undergo stem cell therapy in Canada and the first person in the country to be treated for HIE with stem cells.


Dec 2016   Literature review finds umbilical cord clamping at 30-60 secs after term birth ensures safe outcome for baby and adequate cord blood collection.
Dec 2016   Fraction of cord blood collections suitable for transplant goes down by a factor of 7 when cord clamping delay exceeds 1 minute.


Nov 2016   Slides from Parent's Guide to Cord Blood Foundation at Phacilitate Cord Blood and Tissue Webinar 16 Nov. 2016. All presentations will be archived.
Nov 2016   Neha is now a healthy six year old after a cord blood transplant from her brother thanks to the family cord blood bank Babycell in India.
Nov 2016   We see rapid growth in AMP-based injectable products being offered in the U.S., and targeted specifically for allogeneic use. Does this meet FDA guidance?

Newsletter Sign-up

All fields are required
The materials and information included in this electronic newsletter (Newsletter), including advertisements, are provided as a service to you and do not reflect endorsement by the Parent's Guide to Cord Blood Foundation (the "Foundation"). The Foundation is not responsible for the accuracy and completeness of information provided by guest authors, outside sources, or on websites linked to the Newsletter. The Foundation reserves the right at any time to remove materials and information from the Newsletter without communication with the author or organization. Access to and use of all Newsletter information is at the user's own risk. The Foundation is not liable for any damages of any kind, nature or description (whether direct, consequential or punitive) arising out of or relating to information referenced in the Newsletter, or related in any way to the user's access to the Newsletter. The Foundation's Terms of Use is expressly incorporated herein. Questions can be directed to